PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma

Exclusion Criteria

• •1. Age \> 65 or \< 18.
• •2. Receiving radiotherapy or chemotherapy or targeted therapy or immunotherapy previously.
• •3. Severe cerebrovascular disease/canker/psychosis.
• •4. Has active autoimmune disease, except type I diabetes, hypothyroidism treated with replacement therapy, and skin disease that doesn't require systemic treatment (e.g., vitiligo, psoriasis, or alopecia).
• •5. Has any condition that required systemic corticosteroid (equivalent to prednisone \>10mg/d) or other immunosuppressive therapy within 28 days before informed consent. Patients who received systemic corticosteroid equivalent to prednisone ≤10mg/d, inhale or topical corticosteroid will be allowed.
• •6. Has a known history of active TB (bacillus tuberculosis) within 1 year; patients with adequately treated active TB over 1 year ago will be allowed.
• •7. Suffering from active infection diseases and in need of treatment.
• •8. Has received a live vaccine within 30 days before informed consent or will receive a live vaccine in the near future.
• •9. Pregnant or breastfeeding.
• •10. Prior malignancy within 5 years, except in situ cancer, adequately treated non-melanoma skin cancer and papillary thyroid carcinoma.
• •11. Has known allergy to large molecule protein products or any compound of PD-1 antibody.
• •12. Has a known history of the human immunodeficiency virus (HIV) infection.
• •13. Any other condition, including symptomatic heart failure, unstable angina, myocardial infarction, active infection requiring systemic therapy, mental illness or domestic/social factors, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interferes with the interpretation of the results.